Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ATX TELMISARTAN, TELMISARTAN RY, TELMISARTAN GXP, G-SARTAN, TELMISARTAN GPPL, TELMISARTAN JL (Generic Partners Pty Ltd)
Product name
ATX TELMISARTAN, TELMISARTAN RY, TELMISARTAN GXP, G-SARTAN, TELMISARTAN GPPL, TELMISARTAN JL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
170 working days (255)
Active ingredients
telmisartan
Registration type
New generic medicine
Indication
ATX TELMISARTAN, TELMISARTAN RY, TELMISARTAN GXP, G-SARTAN, TELMISARTAN GPPL, TELMISARTAN JL (tablets) are indicated for treatment of hypertension and prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.